Genticel

Genticel Société Anonyme, a clinical stage biotechnology company, develops immunotherapies to prevent cancers caused by the human papillomavirus (HPV). The company develops GTL001, a therapeutic vaccine that is in Phase II clinical trials in Europe, as well as in Phase I clinical trials in the United States for women infected with HPV 16 and/or HPV 18 before the appearance of cervical lesions or cancer. It also develops GTL002, a multivalent immunotherapy, which is in preclinical development that targets various HPV types, including HPV 16 and 18. Genticel Société Anonyme was founded in 2001 and is headquartered in Labège, France.
Type
Public
HQ
Labège, FR
Founded
2001
Employees
34 (est)
Genticel was founded in 2001 and is headquartered in Labège, FR

Genticel Locations

Labège, FR

Genticel Metrics

Genticel Summary

Market capitalization

€46.6 M

Closing share price

€2.82
Genticel's latest market capitalization is €46.6 M.

Genticel Market Value History

Genticel Company Life